Norges Bank
TCRR

Norges Bank’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Norges Bank’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,000
Closed -$436K – 2142
2019
Q1 		$436K Buy
+25,000
New +$443K ﹤0.01% 2079

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank's TCRR Position: Q2 2019 in Review

Norges Bank sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2019, closing a stake of 25,000 shares — an estimated $436K sold.

Norges Bank first reported a position in TCRR in Q1 2019 and held it in 1 quarter. The position peaked at $436K in Q1 2019. 33 funds tracked by Wall St. Rank hold TCRR as of Q2 2019.

  • Norges Bank reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Norges Bank sold 25,000 TCR2 Therapeutics Inc. Common Stock shares in Q2 2019, an estimated $436K.
  • Norges Bank first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Norges Bank's TCR2 Therapeutics Inc. Common Stock position peaked at $436K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2019.

Based on Norges Bank's 13F filing for Q2 2019, filed 9 Aug 2019.